Definition of "antiviral design"

Later, Thompson says: "[Mastodon] was engineered specifically to create _friction — _to slow things down a bit. This is a big part of why it behaves so differently from mainstream social networks."

The intentional design decisions on Mastodon slow user activity.

Kozlov, M. (2022). Why scientists are racing to develop more COVID antivirals. Nature, 601(7894), 496–496. https://doi.org/10.1038/d41586-022-00112-8

Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., Zepeda, S. K., Papa, G., Kemp, S. A., Ikeda, T., Toyoda, M., Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., … Gupta, R. K. (2022). Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature, 1–1. https://doi.org/10.1038/s41586-022-04474-x

CNN, A. S. (n.d.). Pfizer begins Phase 2 and 3 trial of Covid-19 antiviral Paxlovid in children ages 6 to 17. CNN. Retrieved 22 March 2022, from https://www.cnn.com/2022/03/09/health/pfizer-paxlovid-pediatric-trial/index.html

Mancini, D. P., & Smyth, J. (2022, February 16). Merck struggles to win European approval for Covid-19 antiviral pill. Financial Times. https://www.ft.com/content/2cf0b6cc-b07b-4ff9-a833-42eb1798a576

Academics: Viral Evolution Scenarios, 10 February 2022. (n.d.). GOV.UK. Retrieved February 14, 2022, from https://www.gov.uk/government/publications/academics-viral-evolution-scenarios-10-february-2022

Anthony J Leonardi, PhD, MS. (2022, January 22). Wow. This is concerning. H/t @ForesightWisdom it is learning to become more chronic. Https://t.co/XwFR4D0kiy [Tweet]. @fitterhappierAJ. https://twitter.com/fitterhappierAJ/status/1484996537889476610

Tong-Hyung, K. (n.d.). South Korea gets first supply of Pfizer’s COVID-19 pills. Retrieved January 20, 2022, from https://medicalxpress.com/news/2022-01-south-korea-pfizer-covid-pills.html

Mahase, E. (2021). Covid-19: Do vaccines work against omicron—and other questions answered. BMJ, 375, n3062. https://doi.org/10.1136/bmj.n3062

France-Presse, A. (2021, November 17). Pfizer strikes deal to allow generic versions of its Covid pill for world’s poor. The Guardian. https://www.theguardian.com/business/2021/nov/17/pfizer-strikes-deal-to-allow-generic-versions-of-its-covid-pill-for-worlds-poor

Couzin-Frankel, J. (2021). Antiviral pills could change pandemic’s course. Science, 374(6569), 799–800. https://doi.org/10.1126/science.acx9605

Divergent trajectories of antiviral memory after SARS-Cov-2 infection. (2021, June 15). https://doi.org/10.21203/rs.3.rs-612205/v1

Stokel-Walker, C. (2021). The search for antivirals for covid-19. BMJ, 374, n2165. https://doi.org/10.1136/bmj.n2165

University Of Pittsburgh Scientists Discover Biomolecule That May Neutralize Coronavirus. (2020, September 15). https://pittsburgh.cbslocal.com/2020/09/15/coronavirus-university-pittsburgh-biomolecule-neutralize/

Hoffmann, M., Mösbauer, K., Hofmann-Winkler, H., Kaul, A., Kleine-Weber, H., Krüger, N., Gassen, N. C., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature, 1–5. https://doi.org/10.1038/s41586-020-2575-3

Sun, J., Zhuang, Z., Zheng, J., Li, K., Wong, R. L.-Y., Liu, D., Huang, J., He, J., Zhu, A., Zhao, J., Li, X., Xi, Y., Chen, R., Alshukairi, A. N., Chen, Z., Zhang, Z., Chen, C., Huang, X., Li, F., … Zhao, J. (2020). Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell. https://doi.org/10.1016/j.cell.2020.06.010

Zhou, Q., Chen, V., Shannon, C. P., Wei, X.-S., Xiang, X., Wang, X., Wang, Z.-H., Tebbutt, S. J., Kollmann, T. R., & Fish, E. N. (2020). Interferon-α2b Treatment for COVID-19. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.01061

Zhang, S. (2020, April 8). The Best Hopes for a Coronavirus Drug. The Atlantic. https://www.theatlantic.com/science/archive/2020/04/what-coronavirus-drug-will-look-like/609661/

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hagglof, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., … Nussenzweig, M. C. (2020). Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals [Preprint]. Immunology. https://doi.org/10.1101/2020.05.13.092619

Wang, C., Li, W., Drabek, D. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 11, 2251 (2020). https://doi.org/10.1038/s41467-020-16256-y

Lipsitch, M., Perlman, S., & Waldor, M. K. (2020). Testing COVID-19 therapies to prevent progression of mild disease. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(20)30372-8

Mullard, A. (2020). Flooded by the torrent: The COVID-19 drug pipeline. The Lancet, 395(10232), 1245–1246. https://doi.org/10.1016/S0140-6736(20)30894-1

Una parte en la idea del proyecto funciona en ayudar a crecer a las plantas protegiéndolas de las bacterias u hongos que puedan dañarlas y el hecho que estas partículas sirvan de fungicidas apoyan el hecho de la investigación Notar: El comentario se hace aquí pues en el documento no se pude hacer